EMÄ°719 - DRUG POLICY ANALYSIS
| Course Name | Code | Semester | Theory (hours/week) |
Application (hours/week) |
Credit | ECTS |
|---|---|---|---|---|---|---|
| DRUG POLICY ANALYSIS | EMÄ°719 | 1st Semester | 2 | 0 | 2 | 4 |
| Prequisites | ||||||
| Course language | Turkish | |||||
| Course type | Must | |||||
| Mode of Delivery | Face-to-Face | |||||
| Learning and teaching strategies | Lecture Discussion Question and Answer Preparing and/or Presenting Reports | |||||
| Instructor (s) | Academic members of the Department | |||||
| Course objective | To teach the meaning of the pharmaceuticals within the country?s health policy, follow up the legislations/regulations, and bring up the developments into the agenda in this context. | |||||
| Learning outcomes |
| |||||
| Course Content | Drug expenditures, studying and evaluating pharmaceutical policy, pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies, pharmaceuticals in different countries: developments in regulation and governance, pricing of pharmaceuticals, evaluating pharmaceuticals for health policy in low and middle income country settings. | |||||
| References | 1. International Drug Regulatory Mechanisms (Wertheimer AI, Smith MC), 2. The World Drug Situation (WHO), Evaluating Pharmaceuticals for Health Policy and Reimbursement (Freemantle N, Hill S), 3. Recently published articles Cochrane Database of Systematic Reviews, International Journal of Clinical Pharmacy, Medical Care, Social Science and Medicine | |||||
Course outline weekly
| Weeks | Topics |
|---|---|
| Week 1 | Drug Expenditures |
| Week 2 | Studying and Evaluating Pharmaceutical Policy-Becoming A Part of The Policy and Consultative Process |
| Week 3 | Pharmaceutical Policies: Effects of Reference Pricing, Other Pricing, and Purchasing Policies |
| Week 4 | Multicenter trials: Regulatory perspective |
| Week 5 | The argument for pharmaceutical policy |
| Week 6 | The subsidy of pharmaceuticals: processes and challenges |
| Week 7 | Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle |
| Week 8 | MIDTERM |
| Week 9 | Drug spending in different countries: recent trends and causes |
| Week 10 | Pharmaceuticals in different countries: developments in regulation and governance |
| Week 11 | Development of marketing authorization procedures for pharmaceuticals |
| Week 12 | International pharmaceutical policy: health creation or wealth creation? |
| Week 13 | Priority setting in health care: matching decision criteria with policy objectives |
| Week 14 | Pricing of pharmaceuticals |
| Week 15 | Preparation for final exam |
| Week 16 | FINAL EXAM |
Assesment methods
| Course activities | Number | Percentage |
|---|---|---|
| Attendance | 0 | 0 |
| Laboratory | 0 | 0 |
| Application | 0 | 0 |
| Field activities | 0 | 0 |
| Specific practical training | 0 | 0 |
| Assignments | 0 | 0 |
| Presentation | 0 | 0 |
| Project | 0 | 0 |
| Seminar | 0 | 0 |
| Midterms | 1 | 50 |
| Final exam | 1 | 50 |
| Total | 100 | |
| Percentage of semester activities contributing grade succes | 1 | 50 |
| Percentage of final exam contributing grade succes | 1 | 50 |
| Total | 100 | |
WORKLOAD AND ECTS CALCULATION
| Activities | Number | Duration (hour) | Total Work Load |
|---|---|---|---|
| Course Duration (x14) | 14 | 2 | 28 |
| Laboratory | 0 | 0 | 0 |
| Application | 0 | 0 | 0 |
| Specific practical training | 0 | 0 | 0 |
| Field activities | 0 | 0 | 0 |
| Study Hours Out of Class (Preliminary work, reinforcement, ect) | 14 | 2 | 28 |
| Presentation / Seminar Preparation | 1 | 14 | 14 |
| Project | 0 | 0 | 0 |
| Homework assignment | 1 | 14 | 14 |
| Midterms (Study duration) | 1 | 16 | 16 |
| Final Exam (Study duration) | 1 | 20 | 20 |
| Total Workload | 32 | 68 | 120 |
Matrix Of The Course Learning Outcomes Versus Program Outcomes
| D.9. Key Learning Outcomes | Contrubition level* | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |
| 1. Enhances awareness of professional image issues, strengthens cross-disciplinary relationships, and fosters innovation. | X | ||||
| 2. Possesses advanced expertise in research methods and practices. | X | ||||
| 3. Understands that studies on pharmacy management demand adherence to ethical codes and must align with current practices. | X | ||||
| 4. Knows and follows current standards, regulations, and ethical codes. | X | ||||
| 5. Excels in planning innovative research endeavors. | X | ||||
| 6. Uses technological applications during his studies. | X | ||||
| 7. Reports study results and shares them within scientific communities. | X | ||||
| 8. Tracks global advancements in pharmacy management and social pharmacy, actively engaging in national and international projects. | X | ||||
| 9. Enhance communication skills for interdisciplinary studies from the view of social pharmacy aspects. | X | ||||
| 10. Works for the social benefits and pays attention to the ethical codes. | X | ||||
| 11. Understands the importance of social and cultural factors and approaches evaluation critically. | X | ||||
| 12. Highlights pharmacy management's significance in scientific realms and can lead in proposing solutions and regulations. | X | ||||
| 13. Acknowledges the necessity of lifelong learning in scientific studies and keeps pace with national and international advancements for self-improvement. | X | ||||
*1 Lowest, 2 Low, 3 Average, 4 High, 5 Highest